Dyadic International (DYAI) Change in Receivables (2018 - 2026)
Dyadic International (DYAI) posted Change in Receivables of -$89375.0 for Q1 2026, down 151.46% sequentially from $173662.0 in Q4 2025, and down 484.99% YoY from $23214.8 in Q1 2025.
Dyadic International (DYAI) Change in Receivables (2018 - 2026) Analysis & Trends
Dyadic International has reported Change in Receivables for 9 years, with the latest figure at -$89375.0 in Q1 2026.
- Quarterly Change in Receivables fell 484.99% year-over-year to -$89375.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $772867.0 (up 4318.71% YoY) and the FY2025 annual result came in at $846964.0, up 485.99% from the prior year.
- Change in Receivables slipped to -$89375.0 in Q1 2026 per DYAI's latest filing, from $173662.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $649684.0 in Q2 2022 and troughed at -$875849.0 in Q3 2022.
- A 5-year average of $44868.3 and a median of $33666.0 in 2023 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2025: Change in Receivables sank 710.22% in 2022, then soared 8509.72% in 2025.
- Over 5 years, Change in Receivables stood at $68428.0 in 2022, then sank by 50.8% to $33666.0 in 2023, then sank by 410.73% to -$104611.0 in 2024, then surged by 266.01% to $173662.0 in 2025, then sank by 151.46% to -$89375.0 in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$89375.0, $173662.0, and $201442.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | -89,375.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -89,375.00 |
| Mar 31, 2026 | -89,375.00 |
| Dec 31, 2025 | 173,662.00 |
| Dec 31, 2025 | 173,662.00 |
| Sep 30, 2025 | 201,442.00 |
| Sep 30, 2025 | 201,442.00 |
| Jun 30, 2025 | 487,138.00 |
| Jun 30, 2025 | 487,138.00 |
| Mar 31, 2025 | -15,278.00 |
| Mar 31, 2025 | -15,278.00 |
| Dec 31, 2024 | -104,611.00 |
| Dec 31, 2024 | -104,611.00 |
| Sep 30, 2024 | 95,911.00 |
| Sep 30, 2024 | 95,911.00 |
| Jun 30, 2024 | 5,658.00 |
| Jun 30, 2024 | 5,658.00 |
| Mar 31, 2024 | -216,383.00 |
| Mar 31, 2024 | -216,383.00 |
| Dec 31, 2023 | 33,666.00 |
| Dec 31, 2023 | 33,666.00 |